MGTXMeiraGTx Holdings plc
Price
+41%1YEnd-of-day closes, not the intraday tick.
Survival is the story here: start there
Quality shaky, hard red flags, demanding price, growth steady, the market undecided.
We are a vertically integrated, clinical-stage genetic medicines company with a broad pipeline of late-stage clinical programs, including radiation-induced xerostomia, Parkinson’s disease and AIPL1-associated retinal dystrophy. Our clinical programs use targeted local delivery of small doses of genetic medicines to treat both inherited and more common conditions with severe unmet need. The successful development of the clinical pipeline is supported by our internal end-to-end manufacturing capabilities.
In the company’s own words · 10-K filed Mar 30, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
MeiraGTx Holdings plc (MGTX) reported revenue of $321M in Q2 2026 (quarter ended Jun 30, 2026), up 8609% from the same quarter a year earlier. That came with net income of $161M (50% of revenue). For the full year FY2025, revenue was $81M (+145% year on year) and net income −$114M. Its largest product in Q2 2026 was Related Party License at $205M, 64% of the disclosed total, well ahead of Related Party Service at 33%. The next results filing is expected around Nov 12, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 23, 2026On September 22, 2026, the Board of Directors (the “Board”) of MeiraGTx Holdings plc (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, appointed Alan M. Sebulsky to the Board as a Class I director, effective September 23, 2026, with a term that expires at the Company’s 2028 …Director or officer change · Form 8-K
- Aug 13, 2026MeiraGTx Reports Second Quarter 2026 Financial and Operational Results.Earnings release · press release
- Jul 7, 2026Royalty Note Purchase Agreement On June 30, 2026, MeiraGTx Holdings plc (the “Company”) and certain of its subsidiaries entered into a Royalty Note Purchase Agreement (the “Royalty Note Purchase Agreement”), by and among MeiraGTx, LLC, as issuer, the Company and certain of its subsidiaries, as obligors (collectively …Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $321.4MThe company’s own SEC segment disclosure.
- Related Party License$204.6M64%
- Related Party Service$104.9M33%
- Service$11.9M4%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.